KCM Investment Advisors LLC Decreases Holdings in Danaher Corporation $DHR

KCM Investment Advisors LLC decreased its holdings in Danaher Corporation (NYSE:DHR) by 2.4% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 71,797 shares of the conglomerate’s stock after selling 1,791 shares during the period. KCM Investment Advisors LLC’s holdings in Danaher were worth $14,183,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Danaher by 0.4% during the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock valued at $12,296,123,000 after buying an additional 230,966 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock worth $4,016,404,000 after purchasing an additional 612,154 shares during the last quarter. Invesco Ltd. increased its holdings in Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the period. Charles Schwab Investment Management Inc. raised its position in Danaher by 4.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock valued at $867,168,000 after purchasing an additional 163,332 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in Danaher in the 1st quarter worth approximately $833,941,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the company’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 11.10% of the stock is owned by corporate insiders.

Danaher Stock Performance

Shares of DHR stock opened at $209.89 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The company has a market capitalization of $148.26 billion, a price-to-earnings ratio of 43.28, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. Danaher Corporation has a one year low of $171.00 and a one year high of $258.23. The company’s 50-day moving average is $204.02 and its 200 day moving average is $200.32.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.17. The firm had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.71 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were issued a $0.32 dividend. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is presently 26.39%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on DHR. Evercore ISI upped their target price on Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Cowen reiterated a “buy” rating on shares of Danaher in a report on Wednesday, October 22nd. Scotiabank upgraded shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 target price on the stock in a report on Friday, July 11th. Redburn Partners set a $220.00 target price on shares of Danaher in a research report on Wednesday, October 8th. Finally, Robert W. Baird set a $247.00 price target on shares of Danaher in a research report on Wednesday, October 22nd. Eighteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $243.39.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.